EXCLUSIVE: Capricor Therapeutics Inks European Expansion, Commercialization Pact For Lead Asset With Japanese Pharma Firm
Portfolio Pulse from Vandana Singh
Capricor Therapeutics has entered a commercialization and distribution agreement with Nippon Shinyaku for its lead asset, deramiocel, in Europe. The deal includes a $20 million upfront payment, potential milestone payments up to $715 million, and a $15 million equity investment by Nippon Shinyaku. Capricor's stock rose 6.55% premarket.
September 17, 2024 | 1:07 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Capricor Therapeutics has signed a significant agreement with Nippon Shinyaku for the commercialization of deramiocel in Europe, including a $20 million upfront payment and potential milestone payments up to $715 million. Nippon Shinyaku will also invest $15 million in Capricor stock.
The agreement with Nippon Shinyaku significantly enhances Capricor's financial position and market reach, leading to a positive market reaction with a 6.55% premarket stock increase. The deal's terms, including upfront payments and equity investment, provide Capricor with capital for further development and commercialization efforts.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100